AC Immune SA
ACIU
$2.39
-$0.05-2.05%
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 17.73% | -7.71% | |||
| Gross Profit | 101.26% | 7.71% | |||
| SG&A Expenses | 16.67% | -4.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 12.79% | -30.34% | |||
| Total Operating Expenses | 18.29% | -7.66% | |||
| Operating Income | 77.16% | 7.66% | |||
| Income Before Tax | 68.75% | 8.44% | |||
| Income Tax Expenses | -67.65% | 3.03% | |||
| Earnings from Continuing Operations | 68.75% | 8.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 68.75% | 8.44% | |||
| EBIT | 77.16% | 7.66% | |||
| EBITDA | 79.30% | 7.93% | |||
| EPS Basic | 69.47% | 8.54% | |||
| Normalized Basic EPS | 69.49% | 8.53% | |||
| EPS Diluted | 69.47% | 8.54% | |||
| Normalized Diluted EPS | 69.49% | 8.53% | |||
| Average Basic Shares Outstanding | 2.39% | 0.12% | |||
| Average Diluted Shares Outstanding | 2.39% | 0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
